Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Objective: An expert panel convened to reach a consensus on common misconceptions surrounding buprenorphine, a Schedule III partial µ-opioid receptor agonist indicated for chronic pain. The panel also provided clinical recommendations on the appropriate use of buprenorphine and conversion strategies for switching to buprenorphine from a full µ-opioid receptor agonist for chronic pain management. Methods: The consensus panel met on March 25, 2019, to discuss relevant literature and provide recommendations on interpreting buprenorphine as a partial µ-opioid receptor agonist, prescribing buprenorphine before some Schedule II, III, or IV options, perioperative/trauma management of patients taking buprenorphine, and converting patients from a full µ-opioid receptor agonist to buprenorphine. Results: The panel recommended that buprenorphine’s classification as a partial µ-opioid receptor agonist not be clinically translated to mean partial analgesic efficacy. The panel also recommended that buprenorphine be considered before some Schedule II, III, or IV opioids in patients with a favorable risk/benefit profile on the basis of metabolic factors, abuse potential, and tolerability and that buprenorphine be continued during the perioperative/trauma period. In addition, switching patients from a full µ-opioid receptor agonist to buprenorphine should be considered with no weaning period at starting doses that are based on the previous opioid dose. Conclusions: These recommendations provide a framework for clinicians to address most clinical scenarios regarding buprenorphine use. The overall consensus of the panel was that buprenorphine is a unique Schedule III opioid with favorable pharmacologic properties and a safety profile that may be desirable for chronic pain management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The history of buprenorphine. Buprenorphine was originally developed as an analgesic and was subsequently used for OUD before novel delivery systems allowed for approval in chronic pain management [8,9,12,13]. FDA=Food and Drug Administration; OUD=opioid use disorder.](https://figures.cochat.ai/paper-figures/58cc0d7e0c974ec28f2b0cc30c34f79a/understanding-buprenorphine-for-use-in-chronic-pain-expert-opinion-figure-1.jpg)
![Figure 2 Receptor/ligand definitions and applications to buprenorphine at the μ-opioid receptor. *Definition of a partial agonist: a compound with an intermediate intrinsic activity that at full receptor saturation produces less than the maximal effect obtainable with full agonists in some specified set of in vitro or clinical circumstances [25]. Buprenorphine is a potent Schedule III opioid with high binding affinity at the μ-opioid receptor that behaves as a partial agonist on the basis of in vitro studies [7,14,26]. Although buprenorphine has less total intrinsic activity (capacity to activate a receptor to induce multiple signaling pathways) than full μ-opioid receptor agonists, it still effectively stimulates the analgesic signaling pathway from the μ-opioid receptor [7,14,25,27,28]. 3D=three-dimensional; OR=opioid receptor.](https://figures.cochat.ai/paper-figures/70555884c62b4bf48113c2321c3df2a7/understanding-buprenorphine-for-use-in-chronic-pain-expert-opinion-figure-2.jpg)
![Figure 3 Efficacy and tolerability of buprenorphine compared with those of other opioids used for chronic pain. (A) Potential mechanism of action for buprenorphine and (B) conceptual representation of possible effects compared with those of Schedule II opioids such as, but not limited to, fentanyl [33,38,39]. OR=opioid receptor; ORL1=opioid receptor-like 1.](https://figures.cochat.ai/paper-figures/fe01b988dfd948c9948091ab1e0785a9/understanding-buprenorphine-for-use-in-chronic-pain-expert-opinion-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016
Dahlhamer, J., Lucas, J., Zelaya, Nahin, R., Mackey, S., DeBar, L., Kerns, R., Von Korff, M., Porter, L., & Helmick, C. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6736a2 · Cited by 2,598
Consensus development methods, and their use in clinical guideline development.
Murphy, Black, Lamping, McKee, Sanderson, Askham, & Marteau (1998) · Health Technology Assessment · doi:10.3310/hta2030 · Cited by 2,051
Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies
Volkow, N. D., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1507771 · Cited by 1,305
Webster, L. R., & Webster, R. M. (2005) · Pain Medicine · doi:10.1111/j.1526-4637.2005.00072.x · Cited by 1,096 · cited 1×
“, indications of OUD or substance use disorder, heightened risk of overdose, elevated Opioid Risk Tool [ORT] or other screening tool score [68]) may benefit from buprenorphine [69].”
BackgroundSelf-citationA review of chronic pain impact on patients, their social environment and the health care system
Duenas, M., Ojeda, B., Salazar, A., Mico, J. A., & Failde, I. (2016) · Journal of Pain Research · doi:10.2147/jpr.s105892 · Cited by 985
Consensus development methods, and their use in clinical guideline development.
Murphy, M. P., Black, N. A., Lamping, D. L., et al. (1998) · PubMed · Cited by 965
Opioids and the control of respiration
Pattinson, K. T. S. (2008) · British Journal of Anaesthesia · doi:10.1093/bja/aen094 · Cited by 793
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
Opioids and the treatment of chronic pain: Controversies, current status, and future directions.
Rosenblum, A., Marsch, L. A., Joseph, H., & Portenoy, R. K. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0013628 · Cited by 643
AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT
COWAN, A., LEWIS, J. W., & MACFARLANE, I. R. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07532.x · Cited by 528
Research works printed but not linked: 2
- 10. Belbuca [Prescribing Information]. Raleigh, NC: BioDelivery Sciences International, Inc; 2018.
- 11. Butrans [Prescribing Information]. Stamford, CT: Purdue Pharma L.P; 2018.
Cited by
Lagisetty, P., Garpestad, C., Larkin, A., Macleod, C., Antoku, D., Slat, S., Thomas, J., Powell, V. D., Bohnert, A. S. B., & Lin, L. A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108583 · Cited by 112
Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review
Spreen, L. A., Dittmar, E. N., Quirk, K. C., & Smith, M. A. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2676 · Cited by 85
Buprenorphine and its formulations: a comprehensive review
Poliwoda, S., Noor, N., Jenkins, J. S., Stark, C. W., Steib, M., Hasoon, J. J., Varrassi, G., Urits, I., Viswanath, O., Kaye, A. M., et al. (2022) · Health Psychology Research · doi:10.52965/001c.37517 · Cited by 80
Pharmacological Pain Treatment in Older Persons
Pickering, G. P., Kotlińska–Lemieszek, A., Škvarč, N. K., O’Mahony, D., Monacelli, F., Knaggs, R., Morel, V., & Kocot-Kępska, M. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01151-8 · Cited by 67
Jones, K. F., Khodyakov, D., Arnold, R. M., Bulls, H. W., Dao, E., Kapo, J. M., Meier, D. E., Paice, J. A., Liebschutz, J. M., Ritchie, C., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.2191 · Cited by 59
Powell, V. D., Rosenberg, J. M., Yaganti, A., Garpestad, C., Lagisetty, P., Shannon, C., & Silveira, M. J. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24152 · Cited by 55
Jones, K. F., Fu, M. R., Merlin, J. S., Paice, J. A., Bernacki, R., Lee, C. S., & Wood, L. J. (2020) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2020.08.015 · Cited by 45
Treating Chronic Pain with Buprenorphine—The Practical Guide
Case, A. A., Kullgren, J. G., Anwar, S., Pedraza, S. L., & Davis, M. P. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00910-8 · Cited by 43
Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US
Han, B., Jones, C. M., Einstein, E. B., & Compton, W. M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.29409 · Cited by 40
Peckham, A. M., Ball, J., Colvard, M. D., Dadiomov, D., Hill, L. G., Nichols, S. D., Tallian, K. B., Ventricelli, D. J., & Tran, T. H. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab003 · Cited by 32
Top Ten Tips Palliative Care Clinicians Should Know About Buprenorphine
Neale, K., Weimer, M. B., Davis, M. P., Jones, K. F., Kullgren, J. G., Kale, S. S., Childers, J. W., Broglio, K., Merlin, J. S., Peck, S., et al. (2022) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0399 · Cited by 34
Wong, S. S. C., Chan, T. H., Wang, F., Chan, T. C. W., Ho, H. C., & Cheung, C. W. (2023) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006467 · Cited by 32
Chwistek, M., Sherry, D. R., Kinczewski, L., Silveira, M. J., & Davis, M. P. (2023) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2023.06.022 · Cited by 29
Opioids and pituitary function: expert opinion
Gadelha, M. R., Karavitaki, N., Fudin, J., Bettinger, J. J., Raff, H., & Ben-Shlomo, A. (2022) · Pituitary · doi:10.1007/s11102-021-01202-y · Cited by 27
Self-citationHickey, T. R., Costa, G. P. A., de Oliveira, D. S., Podosek, A., Abelleira, A., Avila-Quintero, V. J., & Aquino, J. P. D. (2025) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2024-106014 · Cited by 29
Harden, R. N., Reisfield, G. M., & Gallagher, R. M. (2020) · Pain Medicine · doi:10.1093/pm/pnaa035 · Cited by 26
Silva, M. J., Coffee, Z. H., Yu, C. H., & Martel, M. O. (2021) · Pain Medicine · doi:10.1093/pm/pnab069 · Cited by 25
Long-Acting Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder
Maremmani, I., Demattéis, M., Gorzelańczyk, E. J., Mugelli, A., Walcher, S., & Torrens, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175575 · Cited by 22
Perioperative Buprenorphine Management
Hickey, T. R., Abelleira, A., Acampora, G. A., Becker, W. C., Falker, C. G., Nazario, M., & Weimer, M. B. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.09.001 · Cited by 23
Buprenorphine Buccal Film for Chronic Pain Management
Hale, M. E., Gimbel, J. S., & Rauck, R. L. (2020) · Pain Management · doi:10.2217/pmt-2020-0013 · Cited by 22
Self-citationLow-Dose Initiation of Buprenorphine: A Narrative Review
Edinoff, A. N., Fahmy, O. H., Spillers, N. J., Zaheri, A. R., Jackson, E. D., Witt, A. J. D., Wenger, D. M., Cornett, E. M., Skidmore, K. L., Kaye, A. M., et al. (2023) · Current Pain and Headache Reports · doi:10.1007/s11916-023-01116-3 · Cited by 18
Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and Clearance
Gabrielsson, J., & Hjorth, S. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000524 · Cited by 18
Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement
Karavitaki, N., Bettinger, J. J., Biermasz, N., Christ-Crain, M., Gadelha, M. R., Inder, W. J., Tsourdi, E., Wakeman, S. E., & Zatelli, M. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae023 · Cited by 14
Buprenorphine for Pain: A Narrative Review and Practical Applications
Spinella, S. A., & McCarthy, R. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.01.022 · Cited by 14
A narrative review of buprenorphine in adult cancer pain
Degnan, M., & Mousa, S. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1822163 · Cited by 15
Peppin, J. F., Coleman, J. J., Paladini, A., & Varrassi, G. (2021) · Cureus · doi:10.7759/cureus.18012 · Cited by 15
Dember, L. M., Hsu, J. Y., Bernardo, L., Cavanaugh, K. L., Charytan, D. M., Crowley, S. T., Cukor, D., Doorenbos, A. Z., Edwards, D. A., Esserman, D. A., et al. (2023) · Contemporary Clinical Trials · doi:10.1016/j.cct.2023.107409 · Cited by 14
The utilization of buprenorphine in chronic pain
Urits, I., Pham, C. T., Swanson, D., Berardino, K., Bandi, P., Amgalan, A., Kaye, R. J., Jung, J. W., Kaye, A. D., Paladini, A., et al. (2020) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2020.06.005 · Cited by 13
Diels–Alder Adducts of Morphinan-6,8-Dienes and Their Transformations
Marton, J., Fekete, A., Cumming, P. D., Hosztafi, S., Mikecz, P., & Henriksen, G. (2022) · Molecules · doi:10.3390/molecules27092863 · Cited by 15
Perioperative Management of Extended-release Buprenorphine
Hickey, T. R., Henry, J. T., Edens, E. L., Gordon, A. J., & Acampora, G. A. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001024 · Cited by 13
Fabian, N. J., Mannion, A. J., Jamiel, M., Anderson, D. J., Rower, J. E., Reilly, C. A., Menegas, W., Muthupalani, S., Ta, C., Fox, J. G., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38973-2 · Cited by 12
Björnsson, M. A., Acharya, C., Strandgården, K., & Tiberg, F. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01288-6 · Cited by 12
Opioid Tapering/Detoxification Protocols, A Compendium: Narrative Review
Fishbain, D. A. (2021) · Pain Medicine · doi:10.1093/pm/pnab019 · Cited by 12
Frontline Perspectives on Buprenorphine for the Management of Chronic Pain
Adler, J. A., Mallick‐Searle, T., Garofoli, M., & Zimmerman, A. (2024) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s449748 · Cited by 12
Self-citationFabian, N. J., Moody, D. E., Averin, O., Fang, W. B., Jamiel, M., Fox, J. G., Burns, M. A., & Haupt, J. L. (2021) · Journal of the American Association for Laboratory Animal Science · doi:10.30802/aalas-jaalas-20-000151 · Cited by 10
Consensus statement on chronic pain treatment in cancer survivors
Mamiya, K., Iida, H., Iseki, M., Yamaguch, S., Yonekura, H., Ueno, H., Kosugi, T., Sasara, T., Takao, Y., Takasusuki, T., et al. (2024) · Journal of Anesthesia · doi:10.1007/s00540-024-03427-0 · Cited by 11
Compassionate Care for People with Cancer and Opioid Use Disorder
Jones, K. F., Broglio, K., Ho, J. J., & Rosa, W. E. (2023) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000947480.74410.06 · Cited by 10
Hasoon, J. J., Chitneni, A., Viswanath, O., Urits, I., Imani, F., & Varrassi, G. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4529 · Cited by 9
Heldreich, C., Ganatra, S., Lim, Z. J., Meyer, I., Hu, R., Weinberg, L., & Tan, C. O. (2022) · BMC Anesthesiology · doi:10.1186/s12871-021-01531-2 · Cited by 9
Cascella, M., Capuozzo, M., Ferrara, F., Ottaiano, A., Perri, F., Sabbatino, F., Conti, V., Santoriello, V., Ponsiglione, A. M., Romano, M., et al. (2024) · Translational Medicine UniSa · doi:10.37825/2239-9747.1047 · Cited by 8
Papa, A., Salzano, A. M., Dato, M. T. D., Desiderio, V., Buonavolontà, P., Mango, P., Saracco, E., Tammaro, D., Luongo, L., & Maione, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1454601 · Cited by 8
Management of Chronic Pain in Patients with Substance Use Disorders
Eagen, K., Rabson, L., & Kellum, R. (2022) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2022.01.008 · Cited by 8
Perioperative Management of Extended-Release Buprenorphine: A Narrative Review and Case Series
Hickey, T. R., Meeks, T. W., Oxentine, H., Park, D. C., Abelleira, A., Edens, E. L., Gordon, A. J., & Acampora, G. A. (2023) · Substance Abuse · doi:10.1177/08897077231167043 · Cited by 9
Haunting of the phantom limb pain abolished by buprenorphine/naloxone
Srejic, U., & Banimahd, F. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-237009 · Cited by 8
Jacobs, C., Liu, A., McCrary, B., McCuskee, S., Wexler, M. G., Stidham, E., Zhang, B., Glassberg, J., & Curtis, S. (2025) · Pain Management Nursing · doi:10.1016/j.pmn.2025.04.012 · Cited by 7
Lintzeris, N., & Dunlop, A. J. (2025) · Pain Management · doi:10.1080/17581869.2025.2555164 · Cited by 7
The Challenge of Managing Neuropathic Pain in Children and Adolescents with Cancer
Coluzzi, F., Stefano, G. D., Scerpa, M. S., Rocco, M., Nardo, G. D., Innocenti, A., Vittori, A., Ferretti, A., & Truini, A. (2025) · Cancers · doi:10.3390/cancers17030460 · Cited by 7
Bapat, S., Washburn, M., Tata, V., Fleming, M. L., Abughosh, S., Essien, E. J., & Thornton, J. D. (2022) · Substance Use & Misuse · doi:10.1080/10826084.2022.2112226 · Cited by 7
Trends in Access to Medications for Opioid Use Disorder
Gupta, S., James, A., Miles, J., Samples, H., Crystal, S., & Simon, K. I. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2025.0393 · Cited by 8
Stanicic, F., Grbic, D., Vukicevic, D., & Zah, V. (2024) · Pain Management · doi:10.2217/pmt-2023-0124 · Cited by 6
Conversion of Schedule II Opioids to Buprenorphine Buccal Film: A Retrospective Analysis
Zimmerman, A., Bikdash, R., & Rauck, R. L. (2020) · Pain Medicine · doi:10.1093/pm/pnaa226 · Cited by 7
Self-citationJohn, S., Boorman, D. W., & Potru, S. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001066 · Cited by 6
Edmond, S. N., Wesolowicz, D. M., Snow, J. L., Currie, S., Jankelovits, A., Chhabra, M. S., & Becker, W. C. (2023) · Journal of Pain · doi:10.1016/j.jpain.2023.07.027 · Cited by 6
Biased agonism in psychopharmacology: an opportunity to improve efficacy and safety of treatments
Le, G. H., Wong, S., Bargiota, S. I., Swainson, J., Lo, H. K. Y., Orsini, D. K., Teopiz, K. M., Guillen-Burgos, H. F., Lim, P. K., & McIntyre, R. S. (2025) · CNS Spectrums · doi:10.1017/s109285292510045x · Cited by 6
Pharmacogenomics of buprenorphine - a narrative review
Aravindan, L., Velu, S., Sivam, I., Sivam, S., Tallapaneni, P. S., Ressler, R., Marks, M., Venkataramanan, R., Radhakrishnan, R., & Sadhasivam, S. (2025) · Pharmacogenomics · doi:10.1080/14622416.2025.2546770 · Cited by 6
Arvanian, V. L., Liang, L., Tesfa, A., Fahmy, M., & Petrosyan, H. A. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136583 · Cited by 5
Zah, V., Stanicic, F., Vukicevic, D., & Grbic, D. (2024) · Pain Management · doi:10.1080/17581869.2024.2348989 · Cited by 5
Insurmountable antagonism of human mu opioid receptors by buprenorphine is due to hemi-equilibrium
Wedemeyer, M. J., Chavera, T. S., Berg, K. A., & Clarke, W. P. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177192 · Cited by 5
Suicide risk after abrupt discontinuation of long-term opioid therapy: an observational cohort study
Huang, S., Jiao, T., Guo, S. J., Star, J. A., Bian, J., Wilson, D. L., & Goodin, A. J. (2025) · Pain Medicine · doi:10.1093/pm/pnaf044 · Cited by 6
Wang, A., Shulman, M., Choo, T.-H. J., Pavlicová, M., Langleben, D. D., Nunes, E. V., & Rotrosen, J. (2021) · Addiction Biology · doi:10.1111/adb.13112 · Cited by 5
A Need for Further Education on Buprenorphine in Pain Medicine
Hasoon, J. J., Nguyen, A., Urits, I., Robinson, C., Viswanath, O., & Kaye, A. D. (2023) · Health Psychology Research · doi:10.52965/001c.74958 · Cited by 5
Salay, M., Edwards, K. A., Winstanley, E. L., Bachrach, R. L., Bulls, H. W., Hanmer, J., Liebschutz, J. M., Robbins, J. L., Wilson, J. D., Yu, L., et al. (2024) · Substance Use & Addiction Journal · doi:10.1177/29767342241261562 · Cited by 5
Expecting medication misuse: a proactive approach to drug discovery to prevent fatal overdose
Carry, E., Vasilatis, A., Johnson, A. L., & Ryan, J. W. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2476388 · Cited by 4
At a Crossroads: Opioid Use Disorder, the X-Waiver, and the Road Ahead
Dhillon, J. S., Feulner, L., Beitollahi, A., Kossen, K., & Galarneau, D. W. (2024) · Ochsner Journal · doi:10.31486/toj.23.0074 · Cited by 4
Buprenorphine Use for Analgesia in Palliative Care
Jackson, L. K., Poon, I. O., Garcia, M. A., Imam, S., & Braun, U. K. (2024) · Pharmacy · doi:10.3390/pharmacy12030078 · Cited by 4
Opioid System and Epithelial–Mesenchymal Transition
Łazarczyk, M., Skiba, D. S., Mickael, M., Jaskuła, K., Nawrocka, A., Religa, P., & Sacharczuk, M. (2025) · Pharmaceuticals · doi:10.3390/ph18010120 · Cited by 4
Seecof, O. M., Kuwata, C., DiBiase, J., & Popp, B. (2022) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0182 · Cited by 4
Retrospective Cohort Study of Safety Outcomes Associated with Opioid Rotations to Buprenorphine
Shah, N. K., Chandler, M. W., Cetto, A. V., Luciani, L. L., Painter, J. T., & Bailey, D. (2023) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2023.2200412 · Cited by 4
Outpatient cross-titration to buprenorphine for chronic pain: A retrospective analysis
Ito, S., Welsh, M., Bockman, C., Dale, R., Pilkington, D., & Peperzak, K. A. (2023) · Journal of Opioid Management · doi:10.5055/jom.0839 · Cited by 4
Heroin Use in Older Adults: A Treatment Challenge
Mannelli, P. (2021) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2021.02.039 · Cited by 4
Rau, J., Joseph, R. M., Weise, L., Bryan, J., Wardeh, J., Konda, A., Duplessis, L., & Hook, M. A. (2025) · Journal of Neurotrauma · doi:10.1089/neu.2024.0375 · Cited by 3
Shuman, C. J., Zhang, X., Hall, S. V., Tilea, A. M., Clark, S. J., Vance, A. J., Courant, A., & Zivin, K. (2025) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2025.209720 · Cited by 3
Jose, V., Thekkekara, R. J., Stückler, D., & Greminger, A. (2025) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2025.12.009 · Cited by 3
Buprenorphine Prescribing Among Primary Care Clinicians for Chronic Pain and Opioid Use Disorder
Sohn, N., Lai, B., & Deyo-Svendsen, M. E. (2025) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2025.250039r1 · Cited by 3
Buprenorphine: An anesthesia-centric review
Hickey, T. R., & Acampora, G. A. (2024) · Journal of Opioid Management · doi:10.5055/jom.0901 · Cited by 3
Duarte, S., Rocha-Neves, J. P., Dourado, M., & Ribeiro, H. C. (2025) · Applied Biosciences · doi:10.3390/applbiosci4010003 · Cited by 2
Perioperative Considerations for Medications for Opioid Use Disorder
Harrison, T. K., Kornfeld, H., & Aggarwal, A. K. (2025) · Anesthesiology Clinics · doi:10.1016/j.anclin.2025.07.004 · Cited by 2
You, D. S., Edwards, K. A., Ziadni, M. S., Kim, S., Klein, M. R., Cox, R., Raney, E., Kuchera, J., & Darnall, B. D. (2026) · JMIR Formative Research · doi:10.2196/86070 · Cited by 2
Self-citationApplication Site Reactions from the Buprenorphine Transdermal Patch: A Case Series
Meyer‐Junco, L., Rea, B., Mendoza, K. S., & Fudin, J. (2022) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2022.2051676 · Cited by 2
Self-citationPatel, K. V., Sahni, S., & Taylor, L. F. (2022) · Journal of Osteopathic Medicine · doi:10.1515/jom-2022-0075 · Cited by 2
Pain Management in the Older Adult
Sapell, D., Hale, C., Takeshita, A., & Copenhaver, D. J. (2023) · Springer eBooks · doi:10.1007/978-3-030-01782-8_90-1 · Cited by 2
Barenie, R. E., Bateman, B. T., Connery, H. S., Tsacogianis, T., & Kesselheim, A. S. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209243 · Cited by 2
Pain Management in the Older Adult
Sapell, D., Hale, C., Takeshita, A., & Copenhaver, D. J. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_90 · Cited by 2
Andrassy, B., Mukhdomi, J., Bhaskar, N., Harris, M., & Mukhdomi, T. J. (2025) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2024-106306 · Cited by 2
Ballantyne, J. C., Sullivan, M. D., & Saxon, A. J. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001526 · Cited by 2
Abriola, S. T., Oliver, J. B., & Hurley, R. W. (2025) · Pain Medicine · doi:10.1093/pm/pnaf094 · Cited by 2
Furlan, A. D., & Murphy, L. L. (2022) · Wiley eBooks · doi:10.1002/9781119701170.ch18 · Cited by 2
Azar, P., Kim, J. J., Azarmju, F., Sirohi, K., Machado, J. M., Lau, A., Siu, J. T. P., Ignaszewski, M. J., Montaner, J. S. G., & Krausz, M. R. (2025) · Substance Use Research and Treatment · doi:10.1177/29768357251343612 · Cited by 2
Fornasari, D., & Cuomo, A. (2025) · Pain and Therapy · doi:10.1007/s40122-025-00753-3 · Cited by 1
Investigating mitophagy mechanisms in bronchopulmonary dysplasia through bioinformatics
Li, C., Wang, Y., Wang, X., & Li, Y. (2025) · Pediatric Research · doi:10.1038/s41390-025-04319-z · Cited by 1
Andreieva, I. O., Tarnacka, B., Zalewski, A., & Wiśniowska, J. (2025) · Pharmaceuticals · doi:10.3390/ph18081114 · Cited by 1
Ferron, S., Clavel, A. L., Panopoulos, G., Kaper, G. M., & Gustafson, S. K. (2025) · Journal of Opioid Management · doi:10.5055/jom.0953 · Cited by 1
Ilgen, M. A., Blow, F. C., Piette, J. D., Goldstick, J. E., Lewis, M., Priest, W., Matharu, H., Bourgoise, M., Young, C. A., Ashe, D., et al. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.108081 · Cited by 1
Dayan-Rosenman, D., Diletti-Swenson, S., GHAYALOD, N., & Sokol, R. G. (2026) · Addiction Science & Clinical Practice · doi:10.1186/s13722-026-00653-7 · Cited by 1
Rhee, J. Y., Miller, P., Finnemore, A., Tentor, Z., Durieux, B. N., Ardeljan, L., Lindvall, C. J., Jones, K. F., & Sager, Z. S. (2026) · Neuro-Oncology Practice · doi:10.1093/nop/npag009 · Cited by 1
Gupta, S., Schwartz, K., Bell, L. A., Siegal, N., & Aalsma, M. C. (2026) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2026.100417 · Cited by 1
Can Buprenorphine Be Overdosed? The Ceiling Effect and Its Clinical Implications
Kozińska, R. B., Ślęzak, J., Ilski, I., Podsiadła, M., Biedka, K., & Królewicz, E. (2026) · Pharmaceuticals · doi:10.3390/ph19060903 · Cited by 1
Is buprenorphine safe for the treatment of chronic pain in adults?
Bissaillon, A. L., Mesa, A. S., Schroeder, J., & Raymond, T. J. (2022) · Evidence-Based Practice · doi:10.1097/ebp.0000000000001658 · Cited by 1
Kotlińska–Lemieszek, A. (2022) · Medycyna Paliatywna · doi:10.5114/pm.2022.126738 · Cited by 2
Analgesic methadone prescribing in community health centers among patients with chronic pain
Bailey, S. R., O'Malley, J. P., Hartung, D. M., Huguet, N., Marino, M., & Muench, J. (2023) · Journal of Opioid Management · doi:10.5055/jom.0811 · Cited by 1
Metadata
- Authors
- Webster, L., Gudin, J., Raffa, R. B., Kuchera, J., Rauck, R., Fudin, J., Adler, J., & Mallick-Searle, T.
- Affiliations
- PRA Health Sciences (US)
- Englewood Hospital and Medical Center (US)
- University of Arizona (US)
- Cassava Sciences (United States) (US)
- Carolinas Pain Institute (US)
- Western New England University (US)
- Pacific Pain Medicine Consultants, Encinitas, California
- Division of Pain Medicine, Stanford Medicine Outpatient Center, Redwood City, California, USA
- Corresponding author
- Webster, Lynn
- Venue
- Pain Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-01-09
- Volume
- 21
- Issue
- 4
- Pages
- 714-723
- ISSN
- 1526-2375 (ISSN-L)
- 1526-4637
- PMC
- PMC7139205
- OpenAlex
- W2999420193
- Semantic Scholar
- cc2517b813031b59a622a7fb6090710466afcf83
- Cited by
- 130
- References
- 70
- Citations by year
- 2026: 13 · 2025: 35 · 2024: 20 · 2023: 24 · 2022: 18 · 2021: 14 · 2020: 6
- FWCI
- 13.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Pain Medicine (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- BioDelivery Sciences International, Inc.
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Keywords
- buprenorphine, chronic pain management, opioid conversion, opioid prescribing, perioperative care, trauma management, opioid abuse potential, analgesic efficacy
- MeSH terms
- Analgesics, Opioid, Buprenorphine, Humans, Practice Guidelines as Topic, Receptors, Opioid, mu, Drug Substitution, Chronic Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.